Pterostilbene, silybin, and nicotinamide riboside supplement for exercise-related oxidative stress

Effect of the Combination of Pterostilbene Cocrystal With Silybin and Nicotinamide Riboside on High-Intensity Exercise-Induced Oxidative Stress: A Randomized, Crossover, Placebo-Controlled, Triple-Blind Study

The study will test whether taking a daily supplement that combines pterostilbene, silybin, and nicotinamide riboside reduces oxidative stress after intense exercise in healthy, active men.

Quick facts

• Phase: NA
• Study type: Interventional
• Enrollment: 14 (estimated)
• Ages: 18 Years to 50 Years
• Sex: Male
• Sponsor: Fundació Eurecat (other)
• Locations: 1 site (Reus, Tarragona)
• Trial ID: NCT07024966 on ClinicalTrials.gov

What this trial studies

This randomized, triple-blind, placebo-controlled crossover trial will enroll 14 healthy male amateur runners aged 18–50. Participants will take either the ccPT-SIL-NR supplement or placebo twice daily for 14 days, perform a treadmill session at 80% VO2max, and provide blood and urine samples before and after exercise. After a washout period they will switch treatments and repeat the protocol, with the primary outcome being the change in plasma malondialdehyde (MDA). Secondary outcomes include urinary 8-OHdG and F2-isoprostanes, antioxidant enzyme activities, inflammatory and muscle-damage markers, cortisol, creatinine, and transcriptomic profiling.

Who should consider this trial

Good fit: Ideal participants are healthy, physically active male amateur runners aged 18–50 who run at least three 60-minute vigorous sessions per week and can sustain 45 minutes at high intensity.

Not a fit: People who are female, sedentary, have chronic diseases, are outside the BMI range (<18 or ≥30 kg/m²), or cannot attend the Reus study site are unlikely to benefit from or be eligible for this protocol.

Why it matters

Potential benefit: If effective, the supplement could lower markers of oxidative damage after high-intensity exercise and potentially improve short-term recovery for recreational runners.

How similar studies have performed: Preclinical studies suggest antioxidant effects of pterostilbene, silybin, and nicotinamide riboside, but well-controlled human trials of this specific combination are limited.

Eligibility criteria

Inclusion Criteria:

* Male participants between 18 and 50 years of age who are amateur runners.
* Engage in at least 3 continuous running sessions per week, each lasting 60 minutes, which corresponds to a high level of physical activity according to the International Physical Activity Questionnaire (IPAQ).\*
* Self-report being able to continuously run for 45 minutes at high intensity without difficulty.
* Provide signed informed consent prior to participation in the study.
* Able to read, write, and speak either Catalan or Spanish.

  * High level of physical activity according to the IPAQ: vigorous physical activity (such as running) on at least 3 days per week, with a total energy expenditure ≥1500 MET-min/week.

MET value for vigorous activity = 8 × minutes × days per week.

Exclusion Criteria:

* Body Mass Index (BMI) ≤ 18 kg/m² or ≥ 30 kg/m².
* Presence of chronic diseases associated with increased oxidative stress, such as diabetes, hypertension, chronic obstructive pulmonary disease (COPD), or neurodegenerative diseases.
* Personal history of cardiovascular disease, including myocardial infarction, angina pectoris, stroke, or peripheral artery disease.
* Use of antibiotics within 30 days prior to study entry.
* Use of medications or vitamin supplements that may interfere with the study supplement and exceed 100% of the recommended daily intake within 30 days prior to the start of the study.
* Use of polyphenol supplements, herbal extracts, or phytotherapeutic products that may interfere with the study treatment within 30 days prior to study start.
* Alcohol consumption of 4 or more Standard Drink Units (SDUs) per day or 28 SDUs per week.\*

  \*One SDU is defined as 10 grams of alcohol. This corresponds approximately to: 1 glass of wine (120 mL), 1 beer (330 mL), or 1 small spirit (25 mL); 2 SDUs correspond to 1 glass of brandy or liqueur (55 mL), 1 whiskey (70 mL), or a mixed drink (75 mL).
* Active smoker.
* Unintentional weight loss of more than 3 kg in the past 3 months.
* Known food allergies and/or intolerances related to the study products.
* Presence of anemia.
* Presence of chronic gastrointestinal diseases\* or cancer.\*\*

  \*Chronic gastrointestinal diseases include those in an active phase that may interfere with nutrient absorption. Common examples include gastritis, hiatal hernia, Crohn's disease, celiac disease, irritable bowel syndrome, diverticulitis, diverticulosis, chronic constipation, and ulcerative colitis.

  \*\*Individuals with a history of cancer may be included only if they are in complete remission at the start of the study.
* Participation in another drug clinical trial or nutritional intervention study within 30 days prior to study inclusion.
* Inability to follow the study guidelines.

Where this trial is running

Reus, Tarragona

• Fundació Eurecat — Reus, Tarragona, Spain (RECRUITING)

Study contacts

• Principal investigator: Antoni Caimari, PhD — Fundació Eurecat
• Study coordinator: Antoni Caimari, PhD

Conditions: Oxidative Stress, Physical Activity, Antioxidant Effect, High-intensity exercise, Pterostilbene, Antioxidant supplement, Nutraceutical, Crossover trial